131 related articles for article (PubMed ID: 38042332)
1. Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs.
Jiang Y; Li M; Jiang S; Si L; Gu Y
Value Health; 2024 Mar; 27(3):273-277. PubMed ID: 38042332
[TBL] [Abstract][Full Text] [Related]
2. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
Goldhaber-Fiebert JD; Cipriano LE
Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
[TBL] [Abstract][Full Text] [Related]
3. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
4. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
Preckler V; Espín J
Value Health; 2022 Apr; 25(4):666-675. PubMed ID: 35227598
[TBL] [Abstract][Full Text] [Related]
5. Pricing schemes for new drugs: a welfare analysis.
Levaggi R
Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
[TBL] [Abstract][Full Text] [Related]
6. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
[TBL] [Abstract][Full Text] [Related]
7. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology.
Michaeli DT; Michaeli T
Value Health; 2023 Nov; 26(11):1590-1600. PubMed ID: 37516196
[TBL] [Abstract][Full Text] [Related]
8. Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
Heine RJSD; Thielen FW; Mathijssen RHJ; van Leeuwen RWF; Franken MG; Uyl-de Groot CA
PLoS One; 2024; 19(2):e0293264. PubMed ID: 38300937
[TBL] [Abstract][Full Text] [Related]
9. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
Michaeli DT; Mills M; Kanavos P
Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
[TBL] [Abstract][Full Text] [Related]
10. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
Persson U; Norlin JM
Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
[TBL] [Abstract][Full Text] [Related]
11. Modeling Tiered Pricing Frameworks: A Simulation Approach.
Moradpour J; Zhang W; Grootendorst P; Anis AH; Hollis A
Value Health; 2023 Mar; 26(3):351-358. PubMed ID: 36396022
[TBL] [Abstract][Full Text] [Related]
12. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
13. Not one, but many: developing a multi-indication pricing model for medicines in Belgium.
Maes I; Kok E; De Torck PJ; Mestre-Ferrandiz J; Simoens S
Front Pharmacol; 2023; 14():1199253. PubMed ID: 37841908
[No Abstract] [Full Text] [Related]
14. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.
Yeung K; Li M; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1010-1015. PubMed ID: 28944729
[TBL] [Abstract][Full Text] [Related]
15. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Critchley GJ; Zaric GS
Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
[TBL] [Abstract][Full Text] [Related]
16. Price Models for Multi-indication Drugs: A Systematic Review.
Campillo-Artero C; Puig-Junoy J; Segú-Tolsa JL; Trapero-Bertran M
Appl Health Econ Health Policy; 2020 Feb; 18(1):47-56. PubMed ID: 31523756
[TBL] [Abstract][Full Text] [Related]
17. Insurance access and demand response: Pricing and welfare implications.
Besanko D; Dranove D; Garthwaite C
J Health Econ; 2020 Sep; 73():102329. PubMed ID: 32603854
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
19. The Prescription Drug Pricing Moment: Using Public Health Analysis to Clarify the Fair Competition Debate on Prescription Drug Pricing and Consumer Welfare.
Marciarille AM
J Law Med Ethics; 2017 Mar; 45(1_suppl):45-49. PubMed ID: 28661288
[TBL] [Abstract][Full Text] [Related]
20. Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency.
Garrison LP; Jiao B; Dabbous O
Value Health; 2023 Mar; 26(3):336-343. PubMed ID: 36336584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
